Cheddar is the resident badger. We all have to live in harmony in the beaver pond. With all our new found profits Brandon and I will be renovating the lodge come first thaw. I think we'll incorporate two seperate entrances. He's really not all that bad a dude, just likes to stay dry all the time. Me? well btwn pot plays and boidegradable diapers i have a lot of munching to do.
To answer beaver's question about Kitty's homelife: Kitty is not really a stray, lives in a big house, has some real Kitty's and a couple kittens. This Kitty is a big pharma veteran in Med Chem and Pharm Sci. BTW - big pharma is trying to save every nickel they have by getting scientist from India and China to do the lab work at a cheaper rate without paying all the benefits. They are in a general innovation dearth, in general, but several are doing OK like NOVONORDISC. So, now we are left with big huge pharma and the smaller possibly fast growing companies with newer drugs like we have here. There are a few in the middle like Cubist and FRX that need to grow. I am unsure why TSRX is staying low, but it should not last. I would think somebody would swallow this whole. I am now long 50,000 TSRX shares, waiting for a KABOOM time. :#3
...sounds like a purrrrdy nice litter box Kitty.
Do you think the Chinese or Indians are as gifted wrt to inovating as the talent back home? Already manufacturing & the tech market that has left the US is slowly coming back home to roost finding greener pastures may be cheaper but have their limitations. The US is going through a self actualization process but will eventually come out ahead. If copies & counterfits are what you're after then those are the markets to source from. Big pharma has just become too fat and lazy. They need to be taxed on witholding R&D especially by outsourcing it. Greater incentives are needed to make them spend windfalls on investing in the future or help encentivize upstarts.